Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature

Journal of Neuroimaging

Volumn 12, Issue 4, 2002, Pages 302-309

  Zivadinov, Robert ^a   Zorzon, Marino ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Brain atrophy; Gadolinium enhancement; Longitudinal; Multiple sclerosis; Review article

Indexed keywords

ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; GADOLINIUM PENTETATE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; BRAIN ATROPHY; BRAIN PROTECTION; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; HUMAN; IMAGE ENHANCEMENT; INFLAMMATION; MULTIPLE REGRESSION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROSPECTIVE STUDY; RECURRENT DISEASE; REVIEW;

EID: 0036786182     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2002.tb00137.x     Document Type: Review

References (58)

1. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119:2009-2019.
2. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 2000;214:665-670.
3. Fox NC, Jenkins R, Leary SM, et al. Progressive cerebral atrophy in MS. A serial study using registered, volumetric MRI. Neurology 2000;54:807-812.
4. Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS. Neurology 2000;55:61-65.
5. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773-780.
6. Kappos L, Kesselring J, Radü EW, Johnson E. Measurement of atrophy. In: Kappos L, Kesselring J, Radü EW, Johnson E, eds. Multiple Sclerosis: Tissue Destruction and Repair. London, UK: Martin Dunitz; 2000:91-98.
7. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399.
8. Trapp BD, Peterson J, Richard BS, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
9. Arnold DL, Wolinsky JS, Matthews PM, et al. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):94-101.
10. Liu C, Edwards S, Gong Q, Roberts N, Blumhardt LD. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;66:323-330.
11. Luks TL, Goodkin DE, Nelson SJ, et al. A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis. Mult Scler 2000;6:322-327.
12. Redmond IT, Barbosa S, Blumhardt LD, Roberts N. Shortterm ventricular volume changes on serial MRI in multiple sclerosis. Acta Neurol Scand 2000;102:99-105.
13. Lin X, Blumhardt LD. Inflammation and atrophy in multiple sclerosis: MRI association with disease course. J Neurol Sci 2001;189:99-104.
14. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: 2. Predictive value of the early clinical course. Brain 1989;112:1419-1428.
15. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495-503.
16. Sailer M, O'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999;52:599-606.
17. Brex PA, Jenkins R, Fox NC. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000;54:1689-1691.
18. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469-1504.
19. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
20. Simon JH. Brain and spinal cord atrophy in multiple sclerosis. Adv Mult Scler 2000;10:753-769.
21. Simon JH, Jacobs LD, Campion A, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999;53:139-148.
22. Rovaris M, Comi G, Rocca MA, et al. Short-term volume change in relapsing-remitting multiple sclerosis. Effect of glatiramer acetate and implications. Brain 2001;124:1803-1812.
23. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999;53:1698-1704.
24. Leist TP, Gobbibi MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001;58:57-60.
25. Simon JH. From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmunology 1999;98:7-15.
26. Simon JH, Kinkel RP, Jacobs LD, et al. A longitudinal study of T1-hypointense lesions in relapsing MS: results from the MSCRG trial of interferon beta-1a. Neurology 2000;55:185-192.
27. Zivadinov R, Rudick RA, De Masi R, et al. Effects of intravenous methylprednisolone on brain atrophy in relapsing- remitting multiple sclerosis. Neurology 2001;57:1239-1247.
28. Sailer M, Loseff NA, Wang L, et al. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur J Neurology 2001;8:37-42.
29. Paolillo A, Pozzilli C, Gasperini C, et al. Brain atrophy in relapsing-remitting multiple sclerosis. Relationship with black holes, disease duration and clinical disability. J Neurol Sci 2000;174:85-91.
30. Bakshi R, Benedict RBH, Bermel RA, et al. T2 hypointensity in deep grey matter of patients with multiple sclerosis. Arch Neurol 2002;59:62-68.
31. Phillips MD, Grossman RI, Miki Y, et al. Comparison of T2 lesion volume and magnetization transfer ratio histogram analysis and of atrophy and measures of lesion burden in patients with multiple sclerosis. Am J Neuroradiol 1998;19:1055-1060.
32. Molyenux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339.
33. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964-969.
34. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53:751-757.
35. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304.
36. Wolinsky JS, Narayana PA, Johnson KP, the Copolymer 1 Multiple Sclerosis Study Group, the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler 2001;7:33-41.
37. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment. Neurology 2000;54:813-817.
38. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS. Part II: MRI results. Neurology 2000;54:1734-1741.
39. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000;54:1689-1691.
40. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a. Mult Scler 2000;6:365-372.
41. Weinshenker BG, Bass B, Rice GP. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989;112:133-136.
42. Kremenchutzky M, Cottrel D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;22:1941-1950.
43. Amato, MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to conduct and interpretation of clinical trials. J Neurol Sci 1999;168:96-106.
44. Filippi M, Rovaris M, Iannucci G, et al. Whole brain volume changes in patients with progressive MS treated with cladibrine. Neurology 2000;55:1714-1718.
45. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000;123:2256-2263.
46. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999;5:48-57.
47. Kaplan MR, Meyer Franke A, Lambert S, et al. Induction of sodium channel clustering by oligodendrocytes. Nature 1997;386:724-728.
48. Pfrieger FW, Barres BA. Synaptic efficacy enhanced by glial cells in vitro. Science 1997;277:1684-1687.
49. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991;28:254-260.
50. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994;117:759-765.
51. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
52. Filippi M, Rocca MA, Rizzo G, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 1998;121:2011-2020.
53. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1 a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
54. Kesselring J, Miller DH, MacManus DG, et al. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 1989;52:14-17.
55. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enchancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41:1219-1222.
56. Barkhof F, Tas MW, Frequin ST, et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994;36:382-387.
57. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
58. Oliveri RL, Sibilia G, Valentino P, Russo C, Romeo N, Quattrone A. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998;51:1689-1697.